MPO and rapidly progressive glomerulonephritis: The timing of application for designated intractable diseases is not consistent among medical institutions and physicians; treatment regimens implemented after the application, possibly including the drug or drugs for which financial aid is required, are not reflected in the database, resulting in underestimation of the number of patients with MPO-ANCA-positive RPGN who received additional IVCY or RTX.